

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549**

---

**SCHEDULE 13D/A**

**UNDER THE SECURITIES EXCHANGE ACT OF 1934  
(AMENDMENT NO. 3)\***

---

**Myovant Sciences Ltd.**

(Name of Issuer)

**Common Shares, par value \$0.000017727 per share**  
(Title of Class of Securities)

**G637AM102**  
(CUSIP Number)

**Tsutomu Nakagawa**  
**Senior Director, Global Corporate Strategy**  
**Sumitomo Dainippon Pharma Co., Ltd.**  
**6-8, Doshomachi 2-chome,**  
**Chuo-ku, Osaka 541-0045, Japan**

*Copies to:*

**Benjamin O. Lang**  
**Jones Day**  
**The Okura Prestige Tower**  
**2-10-4 Toranomom, Minato-ku**  
**Tokyo 105-001, Japan**

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

**April 14, 2020**  
(Date of Event Which Requires Filing of this Statement)

---

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

---

NOTE: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to be sent.

---

\* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of section 18 of the Securities Exchange Act of 1934 (the "Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

---

---

1	NAMES OF REPORTING PERSONS  Sumitomo Chemical Co., Ltd.	
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions) (a) <input type="checkbox"/> (b) <input type="checkbox"/>	
3	SEC USE ONLY	
4	SOURCE OF FUNDS (See Instructions)  OO	
5	CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)  <input type="checkbox"/>	
6	CITIZENSHIP OR PLACE OF ORGANIZATION  Japan	
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH:	7	SOLE VOTING POWER
	8	SHARED VOTING POWER  47,488,604
	9	SOLE DISPOSITIVE POWER
	10	SHARED DISPOSITIVE POWER  47,488,604
11	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  47,488,604	
12	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES  <input type="checkbox"/>	
13	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)  52.89% (1)	
14	TYPE OF REPORTING PERSON  CO	

(1) This calculation is based on 89,788,054 Common Shares, \$0.000017727 par value per share, of the Issuer (as defined below), issued and outstanding as of January 31, 2020, as disclosed by the Issuer on its quarterly report on Form 10-Q, as filed with the Securities and Exchange Commission on February 10, 2020.

1	NAMES OF REPORTING PERSONS	
	Sumitomo Dainippon Pharma Co., Ltd.	
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) <input type="checkbox"/> (b) <input type="checkbox"/>	
3	SEC USE ONLY	
4	SOURCE OF FUNDS	
	WC (1)	
5	CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) <input type="checkbox"/>	
6	CITIZENSHIP OR PLACE OF ORGANIZATION	
	Japan	
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH:	7	SOLE VOTING POWER
	8	SHARED VOTING POWER 47,488,604
	9	SOLE DISPOSITIVE POWER
	10	SHARED DISPOSITIVE POWER 47,488,604
11	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 47,488,604	
12	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES <input type="checkbox"/>	
13	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 52.89% (2)	
14	TYPE OF REPORTING PERSON CO	

(1) Working capital from Sumitomo Dainippon Pharma Co., Ltd. was contributed to Sumitovant Biopharma Ltd. for purposes of acquiring additional shares.

(2) This calculation is based on 89,788,054 Common Shares, \$0.000017727 par value per share, of the Issuer (as defined below), issued and outstanding as of January 31, 2020, as disclosed by the Issuer on its quarterly report on Form 10-Q, as filed with the Securities and Exchange Commission on February 10, 2020.

1	NAMES OF REPORTING PERSONS	
	Sumitovant Biopharma Ltd.	
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) <input type="checkbox"/> (b) <input type="checkbox"/>	
3	SEC USE ONLY	
4	SOURCE OF FUNDS  OO	
5	CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)  <input type="checkbox"/>	
6	CITIZENSHIP OR PLACE OF ORGANIZATION  Bermuda	
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH:	7	SOLE VOTING POWER  47,488,604
	8	SHARED VOTING POWER
	9	SOLE DISPOSITIVE POWER  47,488,604
	10	SHARED DISPOSITIVE POWER
11	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  47,488,604	
12	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES  <input type="checkbox"/>	
13	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)  52.89% (1)	
14	TYPE OF REPORTING PERSON  OO	

(1) This calculations is based on 89,788,054 Common Shares, \$0.000017727 par value per share, of the Issuer (as defined below), issued and outstanding as of January 31, 2020, as disclosed by the Issuer on its quarterly report on Form 10-Q, as filed with the Securities and Exchange Commission on February 10, 2020.

This Amendment No. 3 to Schedule 13D (this “Amendment No. 3”) relates to the Common Shares, par value \$0.000017727 per share (“Common Shares”), issued by Myovant Sciences Ltd. (the “Issuer”), and amends the Schedule 13D filed on January 3, 2020 (the “Initial Filing”), as amended by Amendment No. 1 filed on March 18, 2020 and Amendment No. 2 filed on March 26, 2020 (together with the Initial Filing, the “Original Schedule 13D” and, together with this Amendment No. 3, the “Statement”). Capitalized terms used and not defined in this Amendment No. 3 have the meanings set forth in the Original Schedule 13D.

This Amendment No. 3 is being filed by Sumitomo Chemical Co., Ltd., a Japanese corporation (“Sumitomo Chemical”), Sumitomo Dainippon Pharma Co., Ltd., a Japanese corporation (“Sumitomo Dainippon”), and Sumitovant Biopharma Ltd. (formerly known as Vant Alliance Ltd.), a Bermuda exempted company limited by shares (“Sumitovant”) (collectively, the “Reporting Persons”).

This Amendment No. 3 is being filed to amend Item 3 and Item 5 of the Original Schedule 13D as follows:

**Item 3. Source and Amount of Funds or Other Consideration**

Item 3 of the Original Schedule 13D is hereby supplementally amended as follows:

On March 26, 2020, Sumitovant purchased 70,000 Common Shares of the Issuer in the open market at an average price of \$7.9401 per share for an aggregate purchase price of \$555,807, all of which was funded through a contribution of working capital from Sumitomo Dainippon to Sumitovant.

On March 27, 2020, Sumitovant purchased 70,000 Common Shares of the Issuer in the open market at an average price of \$7.975 per share for an aggregate purchase price of \$558,250, all of which was funded through a contribution of working capital from Sumitomo Dainippon to Sumitovant.

On March 30, 2020, Sumitovant purchased 70,000 Common Shares of the Issuer in the open market at an average price of \$7.6538 per share for an aggregate purchase price of \$535,766, all of which was funded through a contribution of working capital from Sumitomo Dainippon to Sumitovant.

On March 31, 2020, Sumitovant purchased 70,000 Common Shares of the Issuer in the open market at an average price of \$7.9712 per share for an aggregate purchase price of \$557,984, all of which was funded through a contribution of working capital from Sumitomo Dainippon to Sumitovant.

On April 1, 2020, Sumitovant purchased 70,000 Common Shares of the Issuer in the open market at an average price of \$7.4614 per share for an aggregate purchase price of \$522,298, all of which was funded through a contribution of working capital from Sumitomo Dainippon to Sumitovant.

On April 2, 2020, Sumitovant purchased 70,000 Common Shares of the Issuer in the open market at an average price of \$7.7298 per share for an aggregate purchase price of \$541,086, all of which was funded through a contribution of working capital from Sumitomo Dainippon to Sumitovant.

On April 3, 2020, Sumitovant purchased 70,000 Common Shares of the Issuer in the open market at an average price of \$7.9275 per share for an aggregate purchase price of \$554,925, all of which was funded through a contribution of working capital from Sumitomo Dainippon to Sumitovant.

On April 6, 2020, Sumitovant purchased 70,000 Common Shares of the Issuer in the open market at an average price of \$8.436 per share for an aggregate purchase price of \$590,520, all of which was funded through a contribution of working capital from Sumitomo Dainippon to Sumitovant.

On April 7, 2020, Sumitovant purchased 70,000 Common Shares of the Issuer in the open market at an average price of \$8.2052 per share for an aggregate purchase price of \$574,364, all of which was funded through a contribution of working capital from Sumitomo Dainippon to Sumitovant.

On April 8, 2020, Sumitovant purchased 70,000 Common Shares of the Issuer in the open market at an average price of \$8.5277 per share for an aggregate purchase price of \$596,939, all of which was funded through a contribution of working capital from Sumitomo Dainippon to Sumitovant.

On April 9, 2020, Sumitovant purchased 70,000 Common Shares of the Issuer in the open market at an average price of \$9.3667 per share for an aggregate purchase price of \$655,669, all of which was funded through a contribution of working capital from Sumitomo Dainippon to Sumitovant.

On April 13, 2020, Sumitovant purchased 70,000 Common Shares of the Issuer in the open market at an average price of \$9.8078 per share for an aggregate purchase price of \$686,546, all of which was funded through a contribution of working capital from Sumitomo Dainippon to Sumitovant.

On April 14, 2020, Sumitovant purchased 70,000 Common Shares of the Issuer in the open market at an average price of \$11.0015 per share for an aggregate purchase price of \$770,105, all of which was funded through a contribution of working capital from Sumitomo Dainippon to Sumitovant.

On April 15, 2020, Sumitovant purchased 70,000 Common Shares of the Issuer in the open market at an average price of per share for an aggregate purchase price of \$733,698, all of which was funded through a contribution of working capital from Sumitomo Dainippon to Sumitovant.

The Common Shares in all such transactions were purchased under a Securities Purchase Plan dated March 13, 2020, by and between Citigroup Global Markets Inc. ("CGMI") and Sumitovant ("10b5-1 Trading Plan"), pursuant to Rule 10b5-1 and Rule 10b-18 of the Securities Exchange Act of 1934, as amended.

**Item 5. Interest in Securities of the Issuer**

Item 5 of the Original Schedule 13D is amended and restated to read as follows:

(a)—(b) The responses of the Reporting Persons to Rows (7) through (13) of the cover pages of this Statement are incorporated herein by reference.

The aggregate 47,488,604 Common Shares beneficially owned by the Reporting Persons represent 52.89% of the issued and outstanding Common Shares based on 89,788,054 Common Shares, issued and outstanding as of January 31, 2020, as disclosed by the Issuer on its quarterly report on Form 10-Q, as filed with the Securities and Exchange Commission on February 10, 2020.

Sumitovant has sole voting power and sole dispositive power with regard to 47,488,604 Common Shares. Each of Sumitomo Chemical and Sumitomo Dainippon has shared voting power and shared dispositive power with regard to such Common Shares. Each of Sumitomo Chemical and Sumitomo Dainippon, by virtue of their relationships to Sumitovant (as disclosed in Item 2 of the Original Schedule 13D), may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Act) the Common Shares which Sumitovant directly beneficially owns. Each of Sumitomo Chemical and Sumitomo Dainippon disclaims beneficial ownership of such Common Shares for all other purposes.

(c) There have been no transactions in Common Shares that were effected during the past sixty days by the Reporting Persons other than as reported in this Statement.

(d) No other person is known by the Reporting Persons to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, Common Shares that may be deemed to be beneficially owned by the Reporting Persons.

(e) Not applicable.

**SIGNATURE**

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: April 16, 2020

SUMITOMO CHEMICAL CO., LTD.

By: /s/ Krunal Shah, as Attorney-In-Fact

Dated: April 16, 2020

SUMITOMO DAINIPPON PHARMA CO., LTD.

By:           /s/ Tsutomu Nakagawa          

Name: Tsutomu Nakagawa

Title: Senior Director

Global Corporate Strategy



Dated: April 16, 2020

SUMITOVANT BIOPHARMA LTD.

By: /s/ Krunal Shah, as Attorney-In-Fact